Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether it is feasible and safe to give research
participants investigational treatment with durvalumab and tremelimumab after they have
completed standard treatment for NSCLC and once they have detectable circulating tumor DNA
(ctDNA) in the blood before there is evidence of disease recurrence on imaging studies. These
investigational agents are a type of immunotherapy, which is a treatment that activates your
own body's immune system to treat cancer.